Safety Evaluation and Effect of Food Supplement Containing Dietary Fiber From Cassava on the Alterations of Physiological Parameters in Overweight Female Volunteers

February 20, 2020 updated by: Jintanaporn Wattanathorn, Khon Kaen University
This study is set up to determine the consumption safety and the effect of a food supplement containing dietary fiber from cassava on the alterations of physiological parameters including fasting blood sugar, HbA1c, insulin resistance, lipid profiles, atherogenic index, blood pressure and gut microbes in overweight female volunteers.

Study Overview

Status

Completed

Conditions

Detailed Description

Cassava is one of the important industrial crops in Thailand. The leftover fiber of cassava is still valuable and can be used as a dietary fiber. The previous study demonstrated that dietary fiber containing cassava fiber was safe for consumption without any contamination of the cyanide and heavy metals. Moreover, the microbial contaminations were within the safety range. The toxicity study revealed that the LD50 of the cassava dietary fiber was more than 5 g/kg body weight (BW) and NOAEL was 3 g/kg BW. The NOAEL was used to calculate the human equivalent dose for determining the effect of cassava dietary fiber in a clinical study.

Cassava dietary fiber consists of water-insoluble fiber such as cellulose more than 50%. The previous study showed that insoluble fiber decreased the risk of type 2 diabetes and increased insulin release. Moreover, a high fiber diet also decreased the fasting glucose and HbA1C in type 2 diabetes volunteer. In addition, the effect of dietary fiber on the reduction of cholesterol was also reported. The previous study reported that the cassava dietary fiber could decrease the total cholesterol, triglyceride but increase high-density lipoprotein in a dyslipidemia rat model. Therefore, the cassava fiber might be the potential food supplement for the control of blood sugar and lipid profiles in human. However, less scientific data support the effect of cassava dietary fiber in human.

Study Type

Interventional

Enrollment (Actual)

75

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Khon Kaen, Thailand, 40002
        • Jitanaporn Wattanathorn

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 60 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Healthy women age between 35-60 years old
  • BMI 23-29.99
  • Blood pressure <140/90 mmHg
  • Fasting plasma glucose < 100 mg/dL

Exclusion Criteria:

  • Presence of any chronic diseases
  • Alcohol addict or consume more than 2 units/day
  • Smoking more than 10 cigarettes per day
  • Medication or herbal medicine usage within 1 month prior to the study
  • Use any medication or food supplement which affect to outcomes
  • Pregnant or breastfeeding women
  • Athlete

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
PLACEBO_COMPARATOR: Placebo capsule
Subject receive the Placebo product for 4 weeks.
Cassava dietary fiber capsule or placebo will be consumed once daily at the recommended doses of each group.
ACTIVE_COMPARATOR: Cassava dietary fiber capsule 1.5 g/day
Subjects receive Cassava dietary fiber capsule at the dose of 1.5 g/day for 4 weeks.
Cassava dietary fiber capsule or placebo will be consumed once daily at the recommended doses of each group.
ACTIVE_COMPARATOR: Cassava dietary fiber capsule 3 g/day
Subjects receive Cassava dietary fiber capsule at the dose of 3 g/day for 4 weeks.
Cassava dietary fiber capsule or placebo will be consumed once daily at the recommended doses of each group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The fasting blood sugar level
Time Frame: Baseline and 4 weeks of intervention
The previous study reported that high dietary fiber could decrease the fasting blood sugar in type 2 diabetes patient. The overweight female volunteer receive food supplement containing dietary fiber from Cassava should show the lower level of fasting blood sugar than the placebo-treated group after 4 weeks of intervention.
Baseline and 4 weeks of intervention
The atherogenic index
Time Frame: 4 weeks of intervention
The atherogenic index is an index composed of triglycerides and high-density lipoprotein cholesterol. It has been used to quantify blood lipid levels and commonly used as an optimal indicator of dyslipidemia and associated diseases. The food supplement containing dietary fiber from Cassava might be able to decrease the atherogenic index in overweight female volunteer. The overweight female volunteer receive food supplement containing dietary fiber from Cassava should show the lower number of the atherogenic index than the placebo-treated group after 4 weeks of intervention.
4 weeks of intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
hemoglobin A1c concentration
Time Frame: 4 weeks of intervention
A hemoglobin A1c (HbA1c) test measures the amount of blood sugar (glucose) attached to hemoglobin. This result shows the average amount of glucose attached to hemoglobin has been over the past three months. The previous study reported that high dietary fiber could decrease the HbA1C in type 2 diabetes patient. The food supplement containing dietary fiber from Cassava might be able to decrease the HbA1C in overweight female volunteer. The overweight female volunteer receive food supplement containing dietary fiber from Cassava should show the lower HbA1C level than the placebo-treated group after 4 weeks of intervention.
4 weeks of intervention
Homeostasis model assessment-insulin resistance (HOMA-IR)
Time Frame: 4 weeks of intervention
HOMA-IR was computed with the formula: fasting plasma glucose (mmol/l) multiplied fasting serum insulin (mU/l) divided by 22.5. Low HOMA-IR values indicate high insulin sensitivity, whereas high HOMA-IR values indicate low insulin sensitivity (insulin resistance). The overweight female volunteers receive food supplement containing dietary fiber from Cassava should show the lower HOMA-IR than the placebo-treated group after 4 weeks of intervention.
4 weeks of intervention
Low-density lipoprotein (LDL) concentration
Time Frame: 4 weeks of intervention
LDL is considered bad cholesterol and a leading cause of atherosclerosis formation. The food supplement containing dietary fiber from Cassava might be able to decrease the LDL level in overweight female volunteer. The overweight female volunteers receive food supplement containing dietary fiber from Cassava should show the lower LDL concentration than the placebo-treated group after 4 weeks of intervention.
4 weeks of intervention
High-density lipoprotein (HDL) concentration
Time Frame: 4 weeks of intervention
HDL is considered as good cholesterol and believed that it acts as a scavenger and carrying of LDL from the arteries back to the liver. The food supplement containing dietary fiber from Cassava might be able to increase the LDL level in overweight female volunteer. The overweight female volunteers receive food supplement containing dietary fiber from Cassava should show a higher HDL concentration than the placebo-treated group after 4 weeks of intervention.
4 weeks of intervention
Triglyceride (TG) concentration
Time Frame: 4 weeks of intervention
TG is one type of fat in the blood which converted from the excess energy from the diet. A high triglyceride level combined with high LDL (bad) cholesterol or low HDL (good) cholesterol is linked with fatty buildups within the artery walls, which increases the risk of heart attack and stroke in an overweight person. The food supplement containing dietary fiber from Cassava might be able to decrease the LDL level in overweight female volunteer. The overweight female volunteers receive food supplement containing dietary fiber from Cassava should show the lower TG concentration than the placebo-treated group after 4 weeks of intervention.
4 weeks of intervention
Cholesterol concentration
Time Frame: 4 weeks of intervention
The high level of cholesterol is a cause of atherosclerosis in the blood vessel. The food supplement containing dietary fiber from Cassava might be able to decrease the cholesterol level in overweight female volunteer. The overweight female volunteers receive food supplement containing dietary fiber from Cassava should show the lower cholesterol concentration than the placebo-treated group after 4 weeks of intervention.
4 weeks of intervention
Body mass index (BMI)
Time Frame: 4 weeks of intervention
The food supplement containing dietary fiber from Cassava might be able to decrease the BMI in overweight female volunteer. The overweight female volunteers receive food supplement containing dietary fiber from Cassava should show the lower BMI than the placebo-treated group after 4 weeks of intervention.
4 weeks of intervention
Gut microbes
Time Frame: 4 weeks of intervention
It has been reported that the dysbiosis can cause the alteration of glucose metabolism, lipid metabolism, and dyslipidemia. Moreover, the high fiber diet causes the elevation of good bacteria in the gut and exert many effects. The food supplement containing dietary fiber from Cassava might be able to increase the good gut microbes in overweight female volunteer. The overweight female volunteers receive food supplement containing dietary fiber from Cassava should show higher gut microbes than the placebo-treated group after 4 weeks of intervention.
4 weeks of intervention
The consumption safety of food supplement containing dietary fiber from Cassava using Systolic and Diastolic Blood pressure
Time Frame: 4 weeks of intervention
If the supplement containing dietary fiber from Cassava is safe, the blood pressure should be within the normal range.
4 weeks of intervention
The consumption safety of food supplement containing dietary fiber from Cassava using the electrocardiogram pattern and QT interval data
Time Frame: 4 weeks of intervention
If the supplement containing dietary fiber from Cassava is safe, the EKG pattern and the QT interval should be within the normal range.
4 weeks of intervention
Consumption safety of food supplement containing dietary fiber from Cassava using blood chemistry
Time Frame: 4 weeks of intervention
The blood chemistry values including renal function test, liver function test, and electrolytes will be determined and the data will be expressed as the number of subjects presented with abnormal blood chemistry value.
4 weeks of intervention
Consumption safety of food supplement containing dietary fiber from Cassava using hematolgical values.
Time Frame: 4 weeks of intervention
The hematological values including red blood cell, white blood cell, hematocrit, and platelet will be determined and the data will be expressed as a number of subjects presented with abnormal hematological value.
4 weeks of intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

February 27, 2019

Primary Completion (ACTUAL)

July 31, 2019

Study Completion (ACTUAL)

August 31, 2019

Study Registration Dates

First Submitted

June 20, 2019

First Submitted That Met QC Criteria

July 6, 2019

First Posted (ACTUAL)

July 9, 2019

Study Record Updates

Last Update Posted (ACTUAL)

February 21, 2020

Last Update Submitted That Met QC Criteria

February 20, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HE611054

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Overweight

Clinical Trials on Cassava dietary fiber capsule

Subscribe